IntrinsiQ President Discusses "Clinical Pathways" at Cancer Center Business Summit
* Reuters is not responsible for the content in this press release.
WALTHAM, Mass.--(Business Wire)-- IntrinsiQ president Jeff Forringer will join a panel of top oncologists discussing best-practices for implementing clinical pathways at the 2009 Cancer Center Business Summit, October 8-9 in Dallas. The panel - and the conference overall - will focus on how leading oncology practices are staying ahead of today`s new economic realities while continuing to advance their quality of care. Standardizing care processes and new evidence-based medicine initiatives are improving quality and reimbursement in oncology practices large and small, nationwide. Forringer will draw from IntrinsiQ`s unmatched oncology treatment data that shows how clinical pathways are created and used in different cancer care settings across the U.S. WHAT: "Clinical Pathways: What, Why and How" Panel WHO: Jeff Forringer, president of IntrinsiQ, LLC WHEN: Thursday, Oct. 8, 2009 from 10:45 a.m. - 12:15 p.m. CT WHERE: Adolphus Hotel, Dallas, Texas About IntrinsiQ IntrinsiQ, LLC is the leading provider of medical oncology clinical information systems and the premier source of US oncology data and analysis. Each month, IntrinsiQ`s clinical software application, IntelliDose®, captures the treatment decisions and details from more than 600 oncologists, for nearly 20,000 unique patients, creating a database unrivaled in accuracy, detail and timeliness of information about the medical oncology care process. IntelliDose ensures patient safety though automation and standards designed to meet the needs of a specific practice, saving staff time, maximizing reimbursement and reducing operating costs. For more information, please visit www.intrinsiq.com. IntrinsiQ Company Contact: Diane Poth, 781-434-3304 diane.poth@intrinsiq.com or IntrinsiQ Media Contact: George Robertson, 617-969-9192 grobertson@corporateink.com Copyright Business Wire 2009
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.


Follow Reuters